Loading clinical trials...
Loading clinical trials...
Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following induction chemotherapy. However, a large majority subsequently relapse and succumb to the disease. Currently, ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Wake Forest University Health Sciences
NCT07500441 · Acute Myeloid Leukemia (AML)
NCT05768932 · Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, and more
NCT05756777 · Acute Myeloid Leukemia (AML)
NCT07451912 · Acute Myeloid Leukemia (AML), CEBPA Mutation, and more
NCT06660368 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
Levine Cancer Institute
Charlotte, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions